A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...
Many nursing home residents are refusing COVID shots this winter, though flu vaccine penetration has remained strong historically.
(Reuters) -Drugmaker Pfizer posted a better than expected fourth quarter profit on Thursday, helped by cost cuts and a ...
Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...
A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...
Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...
R obert F. Kennedy Jr., President Trump’s pick to head the U.S. Department of Health and Human Services (HHS), was grilled by ...
CNN on MSN12d
NIH interim director comes from its research ranks but is known for questioning Covid-19 vaccine mandatesDr. Matthew Memoli, a National Institute of Allergy and Infectious Diseases researcher focused on flu and other respiratory ...
Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...
Dr Sonali Mukherjee-Bose told a colleague there would be ‘no risk and good remuneration’ if they created the fake documents ...
The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback